Existing loss of well control event indicators fall short of predicting events in an accurate and timely manner due to a lack ...

Microsoft retires Defender endpoint data alerting, requiring organizations to switch to Purview DLP to avoid losing ...

Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of ...

What it is. AXPAXLI (OTX-TKI) is an investigational, bioresorbable intravitreal hydrogel implant designed to continuously ...

Q4 2025 earnings call: nimacimab + semaglutide data, higher-dose expansion, Halozyme SC plans, 2026 catalysts—read now.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...

Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track ...

Four substudies did not meet pre-specified primary endpoints -- -- Post hoc analyses show setmelanotide achieved statistically significant BMI reductions in patients with obesity due to a heterozygous ...

The U.S. Environmental Protection Agency (EPA) has awarded nearly $1.9 million to Shannon Speir, an assistant professor of crop, soil, and environmental sciences at the University of Arkansas, to ...

The Environmental Protection Agency has awarded $1.9 million to a researcher at the University of Arkansas to study the ...

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or ...

The amount of heat being trapped by the Earth reached a record high in 2025, according to the United Nations, with scientists ...